Fee: Annual Meeting 2022 registrants: free
AAAP members: $25
Non-members: $50
Part 1: Psilocybin in the treatment of substance use disorders – such as tobacco and psychostimulants
Presenter:
Christopher Pittenger, MD, PhD
Director, Yale Program for Psychedelic Science, Psychiatry; Director, Yale Center for Brain and Mind Health, Yale School of Medicine; Director, Yale OCD Research Clinic, Psychiatry; Director, Neuroscience Research Training Program
Yale Department of Psychiatry
New Haven, Connecticut
Part 2: Reviewing the Design, Outcomes, and the Limitations of the Studies/Data Collection of Large Randomized Controlled Trials
Presenter:
Suresh Muthukumaraswamy, PhD
Associate Professor
School of Pharmacy
Faculty of Medical and Health Sciences
The University of Auckland
Waipapa Taumata Rau
Part 3: Ethical Considerations and Concerns About Patient Safety When Treating with Psychedelics
Presenter:
Paul Appelbaum, MD
Psychiatry, Forensic Psychiatry
Elizabeth K. Dollard Professor of Psychiatry, Medicine and Law, and Director, Division of Law, Ethics and Psychiatry at Columbia
New York, New York
Panel discussion
Moderator:
Karen Drexler, MD
Medical Director, AAAP
Department of Psychiatry and Behavioral Sciences Associate Professor
Emory University School of Medicine
Atlanta, Georgia
Panelist:
Nora Volkow, MD
Director of the National Institute on Drug Abuse (NIDA)
The National Institutes of Health
Panelist:
Bertha Madras, PhD
Professor of Psychobiology
Harvard Medical School
McLean Hospital
Boston, Massachusetts
Special thanks to the AAAP Scientific Program Committee (SPC) and Dr. Nitigna Desai, SPC Chair, for their leadership in organizing this event.
